ClinicalTrials.gg
Active, not recruitingNCT06699836CLOVERUpdated Sep 9, 2026

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

A Phase 2 interventional study of 350 mg leronlimab and 700 mg leronlimab in Metastatic Colorectal Cancer (mCRC), sponsored by CytoDyn, Inc.. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
948th of 1,932
66 · median 64
Started
2025
with 142 others
Phase 2
510 of 2,339
65 open now
Primary completion
2028-01
later than 386 of 628 live
Registered
2,093rd of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 948th largest by enrollment of the 1,932 interventional ones that give a count, is one of 143 that started in 2025, is one of 510 in phase 2, reaches primary completion later than 386 of the 628 other live ones, and was the 2,093rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with MSS, mCRC who have progressed on prior treatment, with optional open label leronlimab plus pembrolizumab cohort for participants who have documented disease progression during the initial treatment period of the study and who continue to meet the initial inclusion and exclusion criteria.

The main questions this study aims to answer are:

  1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in participants with MSS, mCRC who have progressed on prior treatment before participating in the study.
  2. In participants who have documented progressive disease during the initial treatment period of the study, what is the objective response rate when leronlimab is administered in combination with pembrolizumab.
  3. Is leronlimab safe and well tolerated when used in combination with trifluridine and tipiracil+ bevacizumab or in combination with pembrolizumab.
Read the detailed description

This is an open label, randomized, two arm, multi-center study evaluating the efficacy, safety, and tolerability of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with MSS, relapsed or refractory, mCRC who have received and progressed, or are intolerant to, at least two prior standard of care treatment regimes, which may have included fluoropyrimidine, oxaliplatin, or irinotecan chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Approximately 60 participants, 30 participants in each of two arms evaluating either 350 mg or 700 mg of leronlimab, who are 18 years of age or older, with histologically confirmed metastatic colorectal cancer that is microsatellite stable (MSS). Participants will be randomized 1:1 to each arm, where approximately 30 participants will receive 350 mg of leronlimab + trifluridine and tipiracil + bevacizumab and approximately 30 will receive 700 mg of leronlimab + trifluridine and tipiracil + bevacizumab.

Participants who complete 52 weeks of treatment and have complete response (CR), partial response (PR), or stable disease (SD) according to RECIST v1.1, with no documented disease progression since their most recent tumor imaging assessment, may be eligible to enter an Extension Treatment Period and continue treatment for up to an additional 52 weeks. Participants entering the Extension Treatment Period will continue the same dose of leronlimab received during the initial treatment period in combination with trifluridine/tipiracil and bevacizumab.

An optional open-label cohort will evaluate leronlimab in combination with pembrolizumab in participants who have documented disease progression during the initial treatment period of the study and meet the applicable eligibility criteria for the cohort. Participants entering this cohort will receive leronlimab 700 mg subcutaneously once weekly in combination with pembrolizumab 200 mg administered intravenously every 3 weeks. Approximately 12 participants may be enrolled in this cohort and may receive treatment for up to 48 weeks.

03

Conditions studied

  • Metastatic Colorectal Cancer (mCRC)

Keywords

  • Microsatellite Stable
  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Main Study):

  1. Male or female subjects age ≥ 18 years with a history of treated colorectal cancer with unresectable of the primary colorectal cancer to other organs.
  2. If -1 positive, (known or documented), viral load must be \< 50 copies/ml and the participant must be on stable ART for at least 3 months. HIV testing is not required for eligibility determination unless clinically indicated.
  3. Adult patients with metastatic colorectal cancer (mCRC) received and progressed, or are intolerant, of at least two prior standard of care treatment regimes, which may have included fluoropyrimidine-, oxaliplatin-, or irinotecan chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
  4. confirmed for microsatellite stable MSS colorectal cancer by PCR, Immunohistochemistry (IHC) or Next-generation sequencing (NGS).
  5. Have per v1.1
  6. Have an (ECOG) performance status of 0 or 1.
  7. Expected survival of at least three months.
  8. No anti-cancer treatment within the last two weeks or at least 5 half-lives prior to treatment (whichever is shorter), except for palliative radiation therapy from which the patient has recovered from all adverse events.
  9. Patients must have adequate organ and bone marrow function within 28 days prior to the first dosing visit, defined as:

    i. Acceptable liver function:

    1. Total ≤ 1.5 × (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 × ULN (participants with known Gilbert's disease may enroll with Total bilirubin ≤ 2.5 × ULN AND direct bilirubin is ≤1.5 × ULN) (if liver metastases are present, Total bilirubin ≤2.0 × ULN).
    2. (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases).

    ii. Acceptable renal function:

    a) ≥ 30 mL/min iii. Acceptable hematologic status:

    1. ≥ 9 g/dL Note: Criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Participants can be on stable dose of erythropoietin (≥ approximately 3 months).
    2. White blood cells > 2500/µL
    3. > 1500/µL
    4. count > 100 000/µL.
  10. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.

    a) No exceeding 460 milliseconds (ms) for females, no QTC interval exceeding 450 ms for males.

  11. Both male and female patients and their partners of must agree to use two medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or one of the following methods of birth control (intrauterine devices, tubal sterilization or vasectomy) or must practice complete abstinence from intercourse of from study entry to 6 months after the last day of treatment (excluding women who are not of childbearing potential and men who have been sterilized).
  12. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study.
  13. Male participants must agree to use contraception and refrain from donating sperm for at least 6 months after the last dose of study intervention.
  14. Patients must have the ability to understand and the willingness to sign a written prior to registration on study.

Exclusion Criteria (Main Study):

  1. Known severe towards monoclonal antibodies.
  2. Clinically significant, active coronary heart disease and cardiovascular insufficiency with compromised hemodynamics per PI discretion.
  3. Had a known additional that was progressing or had required active treatment within the past 2 years.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, incidentally diagnosed prostate cancer (i.e., during a TURP), carcinoma in situ (breast or cervical), excluding carcinoma in situ of bladder, that had undergone potentially curative therapy are not excluded.

  4. Active (defined as having a positive hepatitis B surface antigen [HBsAg] test) or active infection (defined as detectable hepatitis C virus [HCV] RNA), or other known or suspected viral infections. Routine HBsAg/HCV screening is not mandated; however, participants with known or suspected infection are excluded.
  5. Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention.
  6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  7. Stroke and/or within 6 months prior to screening.
  8. Placement of a cardiac stent or bypass surgery within 6 months of screening.
  9. Tumor invasion of a large vascular structure (e.g., pulmonary artery, superior or inferior vena cava).
  10. Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.

    Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  11. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  12. Inability to follow protocol.
  13. Patients who received Trifluridine + Tipiracil (TAS-102) prior to receiving first study drug dose.
  14. Serious non-malignant or malignant disease (e.g. hepatic compromise, obstructive hydronephrosis, or other conditions which may worsen) that could compromise study objectives in the opinion of the investigator, including recurrent ascites or pleural effusion requiring more than one paracentesis or thoracentesis or a single paracentesis or thoracentesis removing more than 3.0 liters of ascites within 30 days prior to screening.

Inclusion Criteria (Extension Cohort):

All inclusion criteria applicable to the two main study treatment arms (leronlimab 350 mg and leronlimab 700 mg, each in combination with Trifluridine + Tipiracil [TAS-102] and bevacizumab) apply, except Inclusion Criterion #8. Continued treatment with Trifluridine + Tipiracil (TAS-102), with or without bevacizumab, from the main study is allowed.

Exclusion Criteria (Extension Cohort):

All exclusion criteria applicable to the two main study treatment arms (leronlimab 350 mg and leronlimab 700 mg, each in combination with Trifluridine + Tipiracil [TAS-102] and bevacizumab) apply, except Exclusion Criteria #10 and #13. Prior participation in the main study is allowed and continued treatment on Trifluridine + Tipiracil (TAS-102) with or without bevacizumab from the main study is allowed.

Inclusion Criteria (Leronlimab plus Pembrolizumab Cohort):

  1. Meet all applicable inclusion criteria from the main study, except Item #8: No anti-cancer treatment within the last two weeks or at least 5 half-lives prior to treatment (whichever is shorter), except for palliative radiation therapy from which the patient has recovered from all adverse events. Continued treatment on Trifluridine + Tipiracil (TAS-102) with or without bevacizumab from the main study is allowed.
  2. Have adequately recovered from prior therapy, defined as resolution of all clinically significant treatment-related toxicities from prior trifluridine and tipiracil + bevacizumab to Grade ≤1 (or baseline).
  3. Have received their last dose of trifluridine and tipiracil at least 3 weeks prior to the first dose of the leronlimab-pembrolizumab combination.
  4. Have documented disease progression.
  5. Provide written informed consent to participate in the pembrolizumab cohort.

Exclusion Criteria (Leronlimab plus Pembrolizumab Cohort):

  1. Meet all applicable exclusion criteria from the main study, except Items #10 and #13. Prior participation in the main study is allowed and continued treatment on Trifluridine + Tipiracil (TAS-102) with or without bevacizumab from the main study is allowed.
  2. Evidence of rapidly deteriorating clinical status or disease-related complications that would limit safe participation (e.g., organ dysfunction or failure, hematologic complications), in the opinion of the investigator.
  3. Prior or current evidence of clinically significant immune-mediated or inflammatory conditions (including pneumonitis) that, in the opinion of the investigator, would increase the risk of treatment with pembrolizumab.
  4. Subjects who have entered or are participating in the optional treatment extension phase.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    350 mg dose of leronlimab in combination with trifluridine + tipiracil (TAS-102) + bevacizumab

    Participants will receive leronlimab 350 mg in combination with trifluridine + tipiracil (TAS-102) and bevacizumab during the initial treatment period. Eligible participants who enter the Extension Treatment Period will continue the same treatment for up to an additional 52 weeks. Participants with documented disease progression during the initial treatment period who meet the applicable eligibility criteria may enter the optional open-label cohort and receive 700 mg leronlimab in combination with 200 mg pembrolizumab.

    Drug: 350 mg leronlimab · Drug: 200 mg pembrolizumab

  • Experimental
    700 mg dose of leronlimab in combination with trifluridine + tipiracil (TAS-102) + bevacizumab

    Participants will receive leronlimab 700 mg in combination with trifluridine + tipiracil (TAS-102) and bevacizumab during the initial treatment period. Eligible participants who enter the Extension Treatment Period will continue the same treatment for up to an additional 52 weeks. Participants with documented disease progression during the initial treatment period who meet the applicable eligibility criteria may enter the optional open-label cohort and receive 700 mg leronlimab in combination with 200 mg pembrolizumab.

    Drug: 700 mg leronlimab · Drug: 200 mg pembrolizumab

Interventions

  • Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Also known as: PRO 140

  • Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Also known as: PRO 140

  • Pembrolizumab is a humanized monoclonal antibody that binds to the programmed death receptor-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2.

    Also known as: KEYTRUDA

06

What researchers measure

Primary outcomes

  1. The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC.

    Efficacy will be measured as the effect on objective response rate (ORR) of leronlimab when used in combination with trifluridine and tipiracil + bevacizumab in patients with relapsed, refractory, MSS, mCRC. ORR is defined as the proportion of subjects with the best overall response (BOR) or confirmed CR or confirmed PR according to RECIST v1.1.

    Time frame: From enrolment through end of treatment at 12 months

Secondary outcomes

  1. The efficacy of leronlimab in combination with pembrolizumab in participants with MSS, mCRC who have documented progressive disease (PD) during the initial treatment period of the study.

    Efficacy will be measured as the effect on objective response rate (ORR) of leronlimab when used in combination with pembrolizumab in participants with MSS, mCRC who entered the leronlimab plus pembrolizumab cohort. ORR is defined as the proportion of subjects with the best overall response (BOR) or confirmed CR or confirmed PR according to RECIST v1.1.

    Time frame: From initiation of treatment in the leronlimab plus pembrolizumab cohort through end of treatment, up to 48 weeks.

  2. Assessment of safety and tolerability of leronlimab when used in combination with trifluridine and tipiracil + bevacizumab or in combination with pembrolizumab in patients with relapsed, refractory, MSS, mCRC.

    Treatment Emergent AE's (TEAE) are defined as events with an onset on or after the first treatment. TEAEs will be summarized by treatment group, System Organ Class, and preferred term. The following TEAE summaries will be provided: * All TEAEs * TEAEs related to study drug. * All TEAEs by severity * Serious TEAEs * Serious TEAEs related to study drug. * TEAE reported in 5% or more participants in any treatment group. * TEAEs leading to discontinuation of study treatment. * TEAEs leading to interruption of study treatment. * TEAEs leading to death.

    Time frame: From enrollment through end of treatment, up to approximately 24 months.

  3. Assessment of the duration of response (DOR) of leronlimab in combination with trifluridine and tipiracil + bevacizumab and leronlimab in combination with pembrolizumab in participants with relapsed, refractory, MSS, mCRC.

    The time from the first documentation of response, either partial or complete, to the documentation of the objective tumor progression or until death due to any cause.

    Time frame: From enrolment through end of treatment, up to 48 weeks.

  4. Assessment of PK parameters of leronlimab during the 12-month treatment period.

    PK parameters will be calculated following multiple dosing during the Treatment Period (12 months) and will include the following: * Cmax, Tmax, AUC0-168, AUC0-last, and AUC0-τ, trough concentrations * AUC0-inf, t1/2, CL/F, and Vz/F.

    Time frame: From enrolment through end of treatment at 12 months.

  5. Evaluation of immunogenicity of leronlimab during treatment period and follow-up.

    Incidence of Anti-Drug-Antibodies from pre-dose baseline through 52 weeks of treatment and approximately 30 days post treatment during follow-up. Incidence of Neutralizing Antibodies from pre-dose baseline through 52 weeks of treatment and approximately 30 days post treatment during follow-up.

    Time frame: From enrolment through 12 months and approximately 30 days post treatment follow-up.

  6. Assessment of the DCR (disease control rate) per RECIST criteria (v1.1) for leronlimab in combination with trifluridine and tipiracil + bevacizumab and with pembrolizumab of patients with relapsed, refractory, mCRC.

    The proportion of participants with complete response (CR), partial response (PR), or stable disease (SD) lasting at least 6 weeks as their best overall response during treatment, as determined according to RECIST v1.1.

    Time frame: From enrolment through end of treatment at 24 months.

  7. Assessment of individual progression free survival (PFS).

    Time from the date of first treatment to the first documented objective radiographic tumor progression per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: From first treatment through end of study (up to 160 weeks)

  8. Assessment of individual overall survival (OS).

    Time from date of first treatment until death from any cause.

    Time frame: From first treatment through end of study (up to 160 weeks).

Other outcomes

  1. Exploratory biomarkers correlating with clinical response.

    Measurement of serum CCL2, CCL3, CCL4, and CCL5 levels and evaluation of change from baseline, and assessment of their association with clinical response to study treatment.

    Time frame: From baseline through week 52 and approximately 30 days post-treatment follow-up.

  2. Change in Circulating Tumor Cells (CTCs) From Baseline (Exploratory)

    Evaluation of the change in circulating tumor cells (CTCs; CTCs/mL) in peripheral blood from baseline to response assessment during study treatment.

    Time frame: From baseline through week 52 and approximately 30 days post-treatment follow-up.

  3. Exploratory analysis of CCR5 expression at baseline.

    Assessment of CCR5 expression in CRC tissue (primary or metastatic) at baseline to characterize biomarker status prior to first dose of leronlimab.

    Time frame: From screening through pre-dose on Cycle 1 Day 1 (baseline).

  4. Exploratory Analysis of CCR5 Haplotypes and Clinical Response

    Determination of CCR5 genotype and haplotypes in participants at baseline using blood samples collected prior to initiation of study treatment.

    Time frame: From screening through pre-dose on Cycle 1 Day 1 (baseline).

  5. Exploratory Analysis of PD-L1 Expression on CTCs and/or CAMLs from baseline

    Evaluation of the change in PD-L1 expression on circulating tumor cells (CTCs) and/or cancer-associated macrophage-like cells (CAMLs) from baseline through study follow-up assessments.

    Time frame: From baseline through week 52 and approximately 30 days post-treatment follow-up.

  6. Exploratory Analysis of circulating tumor DNA (ctDNA) from baseline

    Evaluation of the change in ctDNA from baseline.

    Time frame: From baseline through the Extension Treatment Period, up to 104 weeks.

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2028, 31 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 31 months is close to that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 21, 2024
StartActual
Jun 16, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Mar 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06699836
Lead sponsor
CytoDyn, Inc.
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Jun 16, 2025
Primary completion
Jan 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion